Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain i of β2-glycoprotein i

D. M. Wahezi, Norman Todd Ilowite, X. X. Wu, L. Pelkmans, B. Laat, L. E. Schanberg, J. H. Rand

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies (p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30% versus 242 ± 32% (p < 0.0001). Children with SLE and positive anti-DI antibodies had significantly lower mean A5R levels compared to those with negative anti-DI antibodies: mean A5R = 155 ± 24% versus 177 ± 30% (p < 0.0001). In multivariate analysis, anti-DI antibodies (p = 0.013) and lupus anticoagulant (LA) (p = 0.036) were both independently associated with reduced A5R. Children with SLE have significantly reduced annexin A5 anticoagulant activity that is associated with the presence of LA and anti-DI antibodies.

Original languageEnglish (US)
Pages (from-to)702-711
Number of pages10
JournalLupus
Volume22
Issue number7
DOIs
StatePublished - Jun 2013

Fingerprint

Annexin A5
Systemic Lupus Erythematosus
Anticoagulants
Anti-Idiotypic Antibodies
Glycoproteins
Antibodies
Lupus Coagulation Inhibitor
Thrombosis
Pediatrics
Antiphospholipid Antibodies
Atherosclerosis
Multivariate Analysis

Keywords

  • β2-glycoprotein I
  • annexin A5
  • Antiphospholipid syndrome
  • pediatric lupus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain i of β2-glycoprotein i. / Wahezi, D. M.; Ilowite, Norman Todd; Wu, X. X.; Pelkmans, L.; Laat, B.; Schanberg, L. E.; Rand, J. H.

In: Lupus, Vol. 22, No. 7, 06.2013, p. 702-711.

Research output: Contribution to journalArticle

Wahezi, D. M. ; Ilowite, Norman Todd ; Wu, X. X. ; Pelkmans, L. ; Laat, B. ; Schanberg, L. E. ; Rand, J. H. / Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain i of β2-glycoprotein i. In: Lupus. 2013 ; Vol. 22, No. 7. pp. 702-711.
@article{93374f0f1a064b6e99d77126313aa293,
title = "Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain i of β2-glycoprotein i",
abstract = "Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies (p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30{\%} versus 242 ± 32{\%} (p < 0.0001). Children with SLE and positive anti-DI antibodies had significantly lower mean A5R levels compared to those with negative anti-DI antibodies: mean A5R = 155 ± 24{\%} versus 177 ± 30{\%} (p < 0.0001). In multivariate analysis, anti-DI antibodies (p = 0.013) and lupus anticoagulant (LA) (p = 0.036) were both independently associated with reduced A5R. Children with SLE have significantly reduced annexin A5 anticoagulant activity that is associated with the presence of LA and anti-DI antibodies.",
keywords = "β2-glycoprotein I, annexin A5, Antiphospholipid syndrome, pediatric lupus",
author = "Wahezi, {D. M.} and Ilowite, {Norman Todd} and Wu, {X. X.} and L. Pelkmans and B. Laat and Schanberg, {L. E.} and Rand, {J. H.}",
year = "2013",
month = "6",
doi = "10.1177/0961203313490241",
language = "English (US)",
volume = "22",
pages = "702--711",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain i of β2-glycoprotein i

AU - Wahezi, D. M.

AU - Ilowite, Norman Todd

AU - Wu, X. X.

AU - Pelkmans, L.

AU - Laat, B.

AU - Schanberg, L. E.

AU - Rand, J. H.

PY - 2013/6

Y1 - 2013/6

N2 - Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies (p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30% versus 242 ± 32% (p < 0.0001). Children with SLE and positive anti-DI antibodies had significantly lower mean A5R levels compared to those with negative anti-DI antibodies: mean A5R = 155 ± 24% versus 177 ± 30% (p < 0.0001). In multivariate analysis, anti-DI antibodies (p = 0.013) and lupus anticoagulant (LA) (p = 0.036) were both independently associated with reduced A5R. Children with SLE have significantly reduced annexin A5 anticoagulant activity that is associated with the presence of LA and anti-DI antibodies.

AB - Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies (p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30% versus 242 ± 32% (p < 0.0001). Children with SLE and positive anti-DI antibodies had significantly lower mean A5R levels compared to those with negative anti-DI antibodies: mean A5R = 155 ± 24% versus 177 ± 30% (p < 0.0001). In multivariate analysis, anti-DI antibodies (p = 0.013) and lupus anticoagulant (LA) (p = 0.036) were both independently associated with reduced A5R. Children with SLE have significantly reduced annexin A5 anticoagulant activity that is associated with the presence of LA and anti-DI antibodies.

KW - β2-glycoprotein I

KW - annexin A5

KW - Antiphospholipid syndrome

KW - pediatric lupus

UR - http://www.scopus.com/inward/record.url?scp=84879224885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879224885&partnerID=8YFLogxK

U2 - 10.1177/0961203313490241

DO - 10.1177/0961203313490241

M3 - Article

C2 - 23690366

AN - SCOPUS:84879224885

VL - 22

SP - 702

EP - 711

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 7

ER -